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IntroductIon Atherosclerosis is an inflam-
matory vascular disease1 of increasing incidence 
in the developed countries. Mouse has become 
an excellent experimental model of atheroscle-
rosis2 since 1992, when apolipoprotein E (apoE)-
knockout mice were developed.3‑5 More recent-
ly, apoE and low-density lipoprotein receptor-
double knockout (apoE/LDLR-DKO) mice have 
provided numerous possibilities for both study-
ing pathogenesis and testing the effectiveness of 
treatment in a model of atherosclerosis and hy-
perlipidemia.2‑4,6 In apoE/LDLR-DKO mice fed 
with atherogenic Western diet lesion formation 
is greatly accelerated.7
Since inflammation plays an important role in 
atherogenesis, during recent years it has become 
apparent that the 5-lipoxygenase (5-LO) pathway 
may take significant part in modifying the patho-
genesis of atherosclerosis. Enzymes associated 
with the 5-LO pathway are abundantly expressed 
in arterial walls of patients afflicted with various 
lesion stages of atherosclerosis of the aorta and of 
coronary arteries. These data raised the possibili-
ty that antileukotriene drugs may be an effective 
treatment regimen in atherosclerosis.8 
Lipoxygenases are enzymes that catalyze the 
stereospecific dehydrogenation and subsequent 
dioxygenation of polyunsaturated fatty acids with 
the 1.4-cis-pentadiene structure.9 Of special inter-
est for atherosclerosis is the arachidonate 5-LO, 
which was originally identified in polymorpho-
nuclear leukocytes,10 but which over-expression 
was recently demonstrated in macrophages, den-
dritic cells, foam cells, mast cells and neutrophils 
within atherosclerotic vessels. This enzyme gen-
erates an unstable epoxide inter mediate com-
pound leukotriene A4 (LTA4), which is an impor-
tant precursor of LTB4, LTC4 and other cysteinyl 
leukotrienes. Initial observations and the use of 
drugs affecting the 5-LO meta bolism were main-
ly connected with asthma and other inflamma-
tory diseases.11 However, a growing understand-
ing of the role of inflammation in atherosclero-
sis has brought attention to the potential role of 
leukotrienes and their meta bolism. 
First results of the research on the role of li-
poxygenases in atherogenesis were published in 
1999, when Cyrus et al. observed that absence of 
12/15-lipoxygenase (12/15-LO) decreased athero-
genesis in apoE-deficient mice.12 The confirmed 
later13‑20 role of this enzyme in the formation of 
atherosclerotic plaque was explained by oxidation 
of LDL particles in subendothelial space.
In 2002 Mehrabian et al. identified the 5-LO as 
a crucial enzyme contributing to atherosclerosis 
susceptibility in mice.8,21 This observation, after 
a long pause,22 has again focused the attention 
of researchers on the role of leukotrienes in the 
pathogenesis of atherosclerotic plaque.23‑33 There-
fore, the speculations have been risen that anti-
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AbStrAct
Since inflammation plays an important role in atherogenesis, during recent years it has become 
apparent that the 5‑lipoxygenase (5‑LO) pathway may take a significant part in the pathogenesis 
of atherosclerosis. These data raised the possibility that antileukotriene drugs may be an effective 
treatment regimen in atherosclerosis. This review describes the research performed on the apolipo‑
protein E/low‑density lipoprotein receptor‑double knockout mice as a model of atherosclerosis. The 
study has shown that 5‑LO activating protein inhibitors and leukotriene receptor blockers decrease 
atherosclerosis in atherosclerotic mice. The article also discusses the importance of these findings 
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“en face” and “cross-section” methods were used 
to measure atherosclerotic lesions in the whole 
aorta and in the root of aorta. Moreover, the com-
positions of plaques were estimated by measuring 
the numbers of macrophages and T lymphocytes, 
smooth muscle cells and collagen contents.
Ten µm-thick cryosections were cut from the 
aortic root using a standardized protocol.47 Eight 
adjacent sections were collected at 100-µm inter-
vals starting at a 100-µm distance from the ap-
pearance of aortic valves. After fixation in a 4% 
para formaldehyde, sections were stained with 
hematoxylin and oil red O. Images of the aor-
ta were recorded using the digital camera and 
stored as TIFF files. The total area of the lesion 
was measured semi-automatically in each slide 
using the AnalySIS FIVE software. For each an-
imal the mean lesion area was calculated from 
eight sections, reflecting the cross-section area 
covered by atherosclerosis. 
The aorta from the arch to the bifurcation was 
fixed in a 4% formaldehyde, opened longitudi-
nally, pinned onto black wax plates and stained 
with Sudan IV. The aortic lesion area and total 
aortic area were calculated using the LSM Image 
Browser software.
Results were expressed as mean ±SEM. The 
nonparametric Mann-Whitney U test was used 
for analysis of the data. P<0.05 was considered 
as statistically significant.
rESuLtS Aortas differed in the degree of ath-
erosclerosis between the control group and ex-
perimental groups. Measured by the “en face” 
method, the percentage of occupied by Sudan IV 
– stained surfaces were 25.5 ±2.% in the control 
group, whereas in the MK-886 – treated group 
11.16 ±0.7%, in the BAYx1005 group 15.16 ±1.4%, 
and in the montelukast group 17.23 ±1.8%.
The „cross-section” of aortic roots revealed the 
difference in atherosclerotic lesion areas. Mea-
sured in 8 consecutive sections mean surfaces ± 
SEM occupied by oil red O stained changes were 
455,494 ±26,477 µm2 in the control group vs. 
263,042 ±20,736 µm2 in the MK-886 – treated 
group, 278,107 ±21,824 µm2 in the BAYx1005 
group, and 299,201 ±20,373 µm2 in the mon-
telukast group. All these differences were statis-
tically significant.
Finally, it was shown that all studied drugs may 
increase plaque stability by decreasing the num-
ber of macrophages and T lymphocytes and in-
creasing collagen and smooth muscle cell plaque 
content. 
SuMMAry The discussed study showed that 
montelukast – the antagonist of cysteinyl leu-
kotriene receptor also decreases atherosclerosis 
in gene-targeted mice, however, to a lesser extent 
than FLAP inhibitors. This might result from the 
fact that FLAP inhibitors act “upstream” of the 
leukotriene cascade, blocking both leukotriene B4 
and cysteinyl leukotriene production. In contrast, 
montelukast inhibits the cascade “downstream” 
asthmatic drugs could have beneficial effects on 
atherogenesis.11, 34‑37 
Indeed, it has been recently demonstrated that 
the 5-LO substantially contribute to atheroscle-
rosis in both mouse models and humans.38,39 Lat-
er Aiello et al. showed that LTB4 receptor antag-
onism reduced monocytic foam cells in mice.40 
Lotzer et al. pointed that macrophage-derived 
LTs differentially activate cysLT2-Rs via para-
crine stimulation and cysLT1-Rs via auto crine 
and para crine stimulation, during inflammation 
and atherogenesis.41
working hypothesis Therefore, a hypothesis 
has been formulated that leukotriene-inhibit-
ing drugs developed to treat asthma might pro-
tect the heart.11 There are numerous potential tar-
gets that could be useful in the inter vention in 
leukotriene meta bolism in atherosclerosis. Inter-
estingly, the 18 kDa microsomal protein termed 
five lipoxygenase activating protein (FLAP) was 
found to be critical for the regulation of 5-LO 
activity and bio synthesis of leukotrienes within 
certain compartments of plasma membrane. The 
role of FLAP in atherosclerosis was additionally 
confirmed in humans by Helgadottir et al.42 who 
showed that genetic polymorphisms of FLAP are 
associated with myocardial infarction and stroke 
by increasing leukotriene production and inflam-
mation in the arterial wall. 
The 5-LO is abundantly expressed in athero-
sclerotic lesions of apoE and LDLR deficient mice, 
appearing to co-localize with a subset of mac-
rophages but not with all macrophage-staining 
regions.8 Indeed, the results of the current study 
showed that the inhibition of FLAP by MK-886 
or BAYx1005 can significantly prevent the devel-
opment of atherosclerosis in gene-targeted apoE/
LDLR-DKO mice. Moreover, this study showed 
that cysteinyl leukotriene receptor blocker mon-
telukast decreases atherosclerosis in apoE/LDLR-
double knockout mice.43‑45 The findings of the 
present study concerning MK-886 were soon con-
firmed by Back et al. on their model of transgenic 
apoE-/- mice with the dominant-negative trans-
forming growth factor β type II receptor, which 
displays aggravated atherosclerosis.46
MAtErIAL And MEthodS The present study 
used female apoE/LDLR-DKO mice on the mixed 
C57BL/6J × 129/SvJ background. At the age of 
8 weeks mice were put on Western diet (consist-
ing of 21% fat by weight, 0.15% cholesterol by 
weight) for 4 months. Experimental groups (in 
each group n = 10) received the same diet, mixed 
with MK-886 at a dose of 30 mg per kg of body 
weight daily, BAYx1005 at a dose of 18.75 mg per 
kg of body weight daily, and montelukast at a dose 
of 1.25 mg per kg of body weight daily. 
At the age of 24 weeks the mice were put down 
and plasma, hearts and aortas were collected. To-
tal cholesterol and triglyceride levels and cho-
lesterol lipoprotein profile were determined us-
ing the fast protein liquid chromatography, and 
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by blocking only the effect of cysteinyl leukot-
rienes and leaving LTB4 untouched. Currently, 
the important role of LTB4 in atherogenesis is 
undisputable.22,48‑50
These results, together with many previous 
publications11,33‑37,42,46,48,52 demonstrate the need 
for further clinical trials. Surprisingly, Colin D. 
Funk’s research team has recently questioned 
the hypothesis concerning leukotrienes, 5-LO 
and their role in atherogenesis in gene-target-
ed mice, stating that in mouse plaques there is 
no 5-LO over-expression detectable.51 However, 
it still does not exclude the role of leukotrienes 
in human atherogenesis, since in human plaques 
there is abundant 5-LO expression52 which even 
correlates with symptoms of plaque instability. 
Therefore, further research works, mainly clini-
cal trials, are still needed in this field.53
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